Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Neoplasms 7 Neoplasm Metastasis 7 Endometrial Neoplasms 7 Ovarian Neoplasms 5 Triple Negative Breast Neoplasms 4 Breast Diseases 3 Brain Neoplasms 3 Sarcoma 2 Neoplasms by Site 2 Meningioma 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor, Adult 1 Sarcoma, Kaposi 1 Retinoblastoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Osteosarcoma 1 Neurofibromatosis 1 1 Neoplasm, Residual 1 Multiple Myeloma 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1

Interventions

Fulvestrant 4 trastuzumab deruxtecan 2 elacestrant 2 Vinorelbine 2 toripalimab 1 talazoparib 1 ribociclib 1 pyrotinib 1 palbociclib 1 olaparib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 apatinib 1 abemaciclib 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 Radiotherapy 1 RAD1901 1 Letrozole 1 Itraconazole 1 Injections 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Capecitabine 1 Aromatase Inhibitors 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1 AZD9833 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Advanced Breast Cancer × abemaciclib × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡